Once, Twice, Three Times a Finding: Reproducibility of Dendritic Cell Vaccine Trials Targeting Cytomegalovirus in Glioblastoma

Al's Comment:

 They report amazing results - about 35% 5 year survival for glioblastoma.  This is the type of treatment that highlights why our Promising Pathway Bill needs to be passed right now. If the bill was in effect, treatments like this would be readily available to you now.  Under the current regulations, this might not get approved for a few more years or possibly never.


Posted on: 07/30/2020

Once, Twice, Three Times a Finding: Reproducibility of Dendritic Cell Vaccine Trials Targeting Cytomegalovirus in Glioblastoma

 


Click HERE to return to brain tumor news headlines